Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffer Clear all
Completed Phase 2 Interventional

A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

NCT00384852
View directory record Official record
Conditions
Fractures
Interventions
rhBMP-2/CPM
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

NCT00566345
View directory record Official record
Conditions
Influenza
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
Biological · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
3,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Novel Approaches for Prevention

NCT01183689
View directory record Official record
Conditions
Weight Gain
Interventions
Small Behavior Changes, Large Behavior Changes
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 35 Years
Enrollment
599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406
View directory record Official record
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 25, 2026, 7:37 AM EDT
Not listed Not applicable Interventional

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

NCT01213914
View directory record Official record
Conditions
Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions
An FDA approved continuous renal replacement device, Control Group
Device · Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

NCT03769194
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 25, 2026, 7:37 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

NCT06745921
View directory record Official record
Conditions
West Nile Viral Infection
Interventions
HydroVax-001B WNV, Placebo, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 2Phase 3 Interventional

Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC

NCT00423371
View directory record Official record
Conditions
Osteoarthritis
Interventions
sodium hyaluronate, placebo
Device
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

NCT04022382
View directory record Official record
Conditions
Dry Eye
Interventions
Restylane Defyne
Device
Lead sponsor
John C Meyer, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children

NCT00857727
View directory record Official record
Conditions
Agitation, Anesthesia, Pediatrics
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
6 Months to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 25, 2026, 7:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Nasal Protollin in Early Symptomatic Alzheimer's Disease

NCT07187141
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Protollin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

NCT00624351
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 25, 2026, 7:37 AM EDT
Withdrawn Phase 1Phase 2 Interventional

ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)

NCT05433181
View directory record Official record
Conditions
SARS-CoV-2
Interventions
ACE2 Chewing Gum, Placebo Chewing Gum
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Not applicable Interventional Results available

Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation

NCT05614011
View directory record Official record
Conditions
COVID-19
Interventions
RT-PCR Test, Real-time PCR Test
Diagnostic Test
Lead sponsor
QuantuMDx Group Ltd
Industry
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Knoxville, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 4 Interventional Results available

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate oral solution (COS), Sevelamer carbonate
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • North Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study

NCT04593823
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Fairhope, Alabama • Huntsville, Alabama • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

NCT01585181
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Lexington, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

NCT02035267
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
Deoxycholic Acid, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

NCT01032889
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 25, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074
View directory record Official record
Conditions
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Interventions
botulinum toxin neuromodulator, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Encino, California • Santa Monica, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 25, 2026, 7:37 AM EDT